|
|
|
 |
Erik Engebretsen, Chairman of the Board
Erik Engebretsen, born 1948, was elected as a Director of Photocure in March 2001 and Chairman of the Board in March 2002. Mr Engebretsen is a graduate of the Norwegian School of Management and holds an MBA and MS from the University of Wisconsin-Madison. He is the Managing Director of Gezina AS, a private venture and investment company. Previously he has served as Chief Executive Officer and Chief Financial Officer in various public companies. He is also a member of the Board of Directors with a number of public and private companies.
Mr Erik Engebretsen holds directly 27,000 shares in Photocure. In addition, as CEO of Gezina AS, he controls indirectly 1,060,373 shares in the company. He holds no share options in Photocure.
|
 |
Jon Hindar, Director
Jon Hindar, MSc., born 1957, was elected as a Director in Photocure in 2006. He is CEO of NorSun AS. Prior to joining NorSun, Mr. Hindar was Senior Vice President of the Life Sciences Division in Invitrogen. He was president and CEO of Dynal Biotech from 2002 until Invitrogen's acquisition of Dynal in April 2005. Mr. Hindar has 10 years experience in R&D from various positions with Alcatel and BP Chemicals and another 10 years experience in various General Manager roles in the chemical industry. Before joining Dynal, Mr. Hindar was Managing Partner for five years at the Norwegian investment bank; Fondsfinans. Mr. Hindar is an alumni of IMD (Lausanne, Switzerland) where he joined the Executive Development program in 1993/94.
Mr Jon Hindar holds 5,000 shares in Photocure. He holds no share options in the company.
|
|
Kari Eian Krogstad, Director
Kari Eian Krogstad, born 1964, was elected as a Director of Photocure in April 2007. Mrs. Krogstad holds a MSc in molecular biology from the University of Oslo, as well as a business degree from IHM business school. She has 16 years of experience from the life sciences industry, and has held senior management positions within marketing, sales and business operations in globally operating companies such as Nycomed Imaging (now part of GE) and Dynal Biotech ASA. Kari is currently serving as Vice President and General Manager of Invitrogen Dynal AS, a subsidiary of the publicly traded American biotech company Invitrogen Corporation.
Mrs Kari E. Krogstad holds no shares or share options in Photocure.
|
|
Mats Petterson, Director
Mats Petterson, B.Sc. in Economics and Business Administration, was elected as a Director of Photocure in April 2008.
Mats Pettersson is a board member of H. Lundbeck A/S and deputy chairman of the board of SwedenBio AB. He is member of the board of Ablynx NV.
Mats Pettersson joined Pharmacia in 1976, where he held the position of CFO and different business development positions. Before joining Biovitrum, he was Senior Vice President and member of the Management Committee of Pharmacia Corporation. Mats has been responsible for most of the major transforming mergers in Pharmacia over the last ten years and has spent more than 16 years abroad during his career.
Mats Petterson holds no shares or share options in Photocure.
|
|
Eva Steiness, Director
Eva Steiness, MD, D.Sc.(medicine), Professor i Clinical Pharmacology, was elected as a Director in Photocure in April 2008.
Eva Steiness has a long and extensive experience from development and registration of new drugs. She was responsible for R&D and Regulatory Affairs in H. Lundbeck A/S from 1989 to 1998. She revitalized the R&D activities completely and increased focus on the authorities expectations and at the same time marketing’s strategy and needs. The R&D staff increased from 85 to 450 under her leadership, and the productivity and innovation power were very high.
Eva Steiness founded Zealand Pharma A/S in 1998 based on 3 patent applications. She managed the company until 2007, inkluding development of an anti-diabetic compound out-licenced to Sanofi-Aventis.
Eva Steiness holds no shares or share options in Photocure.
|
|
|
|